MEDICAL CANNABIS

CPH’s US listing is happening tonight - trading as OTC: COPHF

Next Investors Jun 11, 2021

Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.

CPH set to expand in $300M Latin American CBD market

Finfeed Archived Jun 04, 2021

The expansion of its comprehensive distribution agreement with leading nutritional supplements company Route2 Pharm Pvt Ltd, will allow for distribution of Creso Pharma Limited's (ASX: CPH, FRA: 1X8) hemp derived therapeutic products sold under the cannaQIX® and CannaDOL brands into Ecuador.

Bod Australia continues to break sales records

Finfeed Archived May 10, 2021

Bod Australia (ASX: BDA) today announced its highest ever monthly sales for its medicinal cannabis prescription products. BDA attributes its current growth to its Australia wide clinical study to test the efficacy of MediCabilis™ when prescribed for conditions including anxiety, insomnia, and Post Traumatic Stress Disorder (PTSD).

Can BDA’s medical cannabis product treat long-COVID symptoms?

Finfeed Archived Mar 18, 2021

Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.

SURPRISE: We are Now Psychedelics Investors

Next Investors Mar 15, 2021

Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.

Creso enters the growing CBD market in sport and recreation

Finfeed Archived Mar 09, 2021

Today, Creso Pharma Limited (ASX:CPH, FRA:1X8) announced a Letter of Interest (LOI) which marks its entry into the CBD market for sport and recreation; an industry whose global valuation is estimated at US$22Bn by 2022 and C$220m in Canada alone.

CPH deliver Financials and Confirms US Cannabis Market Entry

Next Investors Mar 01, 2021

Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are all out of the way now.

Neurotech’s key near-term objectives

Finfeed Archived Jan 21, 2021

Neurotech International Limited (ASX: NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered.

NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await

Finfeed Archived Dec 21, 2020

Neurotech International Ltd (ASX: NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis leads.

Neurotech poised to commence clinical trials in March quarter

Finfeed Archived Dec 16, 2020

Neurotech International Limited (ASX:NTI) has commenced a stage 1 clinical product formulation and development studies and anticipates entering clinical trials in the March quarter next year.

Changes to OTC cannabis sales just around the corner

Finfeed Archived Nov 26, 2020

The Therapeutic Goods Administration (TGA) will shortly bring down its final decision regarding a major regulatory change in the distribution of cannabidiol (CBD) products in Australia, which could hellp stocks such as Creso Pharma (ASX: CPH).

What does a Kamala Harris Vice Presidency mean for cannabis legalisation?

Finfeed Archived Aug 31, 2020

Joe Biden announced that Kamala Harris is his pick for Vice President, should he win the upcoming US Presidential election in November. But what could a Biden/Harris ticket mean for cannabis legalization?

The world in medical cannabis and weed this week

Finfeed Archived May 01, 2020

The final week in April has proven to be a big week in the cannabis sector, with several global milestones expected in May.

Knee osteoarthritis treatment delivers Regeneus a A$1.6M milestone payment

Finfeed Archived Mar 20, 2020

Regeneus Ltd (ASX: RGS) today received a non-refundable milestone payment of ¥100M (approx. A$1.6M) from Kyocera Corporation (TYO:6971).

CPH Secures Two Execs from the World’s Largest Cannabis Company

Next Investors Archived Mar 11, 2020

ASX Junior Creso Pharma (ASX: CPH) has appointed two former Canopy executives to the senior management team of its wholly-owned Mernova Medical Inc. in Nova Scotia, Canada.

Medical Cannabis